New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favourable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
- EMEA Innovative Medicine
- New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favourable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favourable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
- X (Twitter)
Copy link